Neoaduvant chemotherapy woth FOLFOXIRI and anti-EGFR monoclonal antibody for colorectal cancer with liver metastasis - Neoaduvant chemotherapy woth FOLFOXIRI and anti-EGFR monoclonal antibody for colorectal cancer with liver metastasis

Start Date01 May 2011

Sponsor / Collaborator

The University of Tokushima

EUCTR2006-000871-13-DE

/ Not yet recruitingNot Applicable

A Phase I/II, Open Label, Dose-Escalating Study Evaluating the Safety and Efficacy of the Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody EMD 72000 (Matuzumab) in Combination with the EGFR Tyrosine Kinase Inhibitor Tarceva (Erlotinib) in Subjects with Recurrent Advanced Non-Small-Cell Lung Cancer

Start Date09 Aug 2006

Sponsor / Collaborator

Merck KGaA

NCT00215644

/ CompletedPhase 2

Randomized Phase II Open-Label Controlled Study of EMD 72000 (Matuzumab), in Combination With the Chemotherapy Regimen ECX or the Chemotherapy Regimen ECX Alone as First-line Treatment in Subjects With Metastatic Esophago-Gastric Adenocarcinoma

The purpose of this study is to compare the effectiveness and safety of experimental treatment matuzumab and ECX chemotherapy, with ECX chemotherapy. Participants invited to take part have metastatic cancer of the esophagus (gullet) or stomach.

Start Date31 Aug 2005

Sponsor / Collaborator

Merck KGaA

100 Clinical Results associated with Matuzumab

100 Translational Medicine associated with Matuzumab

100 Patents (Medical) associated with Matuzumab

153

Literatures (Medical) associated with Matuzumab

01 Feb 2025·ELECTROPHORESIS

Evaluation of a cIEF Fractionation Workflow for Offline MS Analysis of Charge Variants of the Monoclonal Antibody Matuzumab

Article

Author: Wilke, Yannick ; Wittmann, Antonia ; Grammel, Nicolas ; Wätzig, Hermann

ABSTRACT:

Biological drugs like monoclonal antibodies require careful analysis and characterization to ensure product quality, safety, and efficacy. Charge variants of the molecule are of key interest and are analyzed using imaged capillary isoelectric focusing (icIEF). However, deeper characterization of these variants poses challenges. Two workflows for their characterization exist: an ion‐exchange chromatography method for variant collection before mass spectrometry (MS) analysis, which is labor‐intensive, and direct coupling of CE to MS, which allows detailed structural characterization but has limitations, for example, due to incompatibilities with ES ionization using high BGE concentrations. This study evaluates a platform that fractionates charge variants for offline MS analysis. The suitability of a procedure in which analytical icIEF methods are converted into preparative cIEF fractionation methods by increasing the sample concentration and adding 20 mM arginine as a cathodic spacer was tested. After chemical mobilization and fraction collection, the identity of the fractions was determined by fluorescence measurement and reinjection of the protein‐containing fractions, using the previously developed analytical icIEF method. MS was subsequently performed. The general suitability of the workflow was demonstrated using Matuzumab. Transferring the analytical method from a concentration of 0.2 to 1.2 mg/mL in fractionation yielded an identical number of peaks and visually comparable peak profiles. The preparative separation took 50 min, with an additional 25 min for mobilization and 45 s per fraction collection, totaling approximately 2.5 h. Verification of charge variant isolation was straightforward via analytical icIEF. Following fractionation, MS allowed for the identification of the main peaks. Preliminary results with other antibodies indicated that the concentration range for MS experiments needs further investigation. Future work will aim to optimize sensitivity, selectivity, analysis time, and reproducibility.

22 Jan 2025·PHARMACOGENOMICS

Treatment of extended RAS/ BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations

Review

Author: Voutsadakis, Ioannis A.

Receptor tyrosine kinase pathways are frequently deregulated in cancer. Inhibiting these pathways with small molecule inhibitors or monoclonal antibodies has become a crucial addition to the therapeutic armamentarium in oncology. Since the introduction of drugs that target receptor tyrosine kinase pathways, it has become evident that not all patients respond to treatment. Therefore, biomarkers to predict response and benefit of drugs targeting tyrosine kinases have been sought. Monoclonal antibodies targeting the Epidermal Growth Factor Receptor (EGFR), one of the four receptors of the EGFR family were among the first targeted therapies used in solid tumors. Two drugs of this class, cetuximab and panitumumab, have been used in patients with metastatic colorectal cancer initially without any biomarker requirement. Soon, it became clear that responses were mostly observed in patients without mutations in KRAS oncogene. Currently, additional mutations of the pathway, including non-exon 2 mutations in KRAS, mutations in the homologous GTPase NRAS, in kinase BRAF and PIK3CA and other pathway proteins, have been added in the evaluation for responsiveness prediction to cetuximab and panitumumab. In this review, the predictive biomarker landscape for anti-EGFR monoclonal antibody inhibitors in metastatic colorectal cancers with no extended RAS and BRAF mutations will be examined.

01 Oct 2024·Cancer research communications

Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study

Article

Author: Sun, Ryan ; Saleem, Sadia ; Wang, Xiaoping ; Litton, Jennifer K. ; Bisen, Ajit K. ; Mittendorf, Elizabeth A. ; White, Jason B. ; Hill, Holly A. ; Hortobagyi, Gabriel N. ; Yam, Clinton ; Kong, Elisabeth ; Damodaran, Senthil ; Valero, Vicente ; Oke, Oluchi ; Murthy, Rashmi K. ; Korkut, Anil ; Patel, Miral ; Koenig, Kimberly B. ; Ramirez, David L. ; Moulder, Stacy L. ; Chen, Ken ; Rauch, Gaiane M. ; Huo, Lei ; Arun, Banu K. ; Ding, Qing-Qing ; Clayborn, Alyson R. ; Tripathy, Debu ; Abouharb, Sausan ; Brewster, Abenaa M. ; Chang, Jeffrey T. ; Lim, Bora ; Booser, Daniel J. ; Ravenberg, Elizabeth E. ; Thompson, Alastair M. ; Adrada, Beatriz E. ; Ueno, Naoto T. ; Candelaria, Rosalind P. ; Ibrahim, Nuhad K. ; Bassett, Roland L.

Abstract:

Purpose::

Epidermal growth factor receptor (EGFR) pathway activation causes chemotherapy resistance, and inhibition of the EGFR pathway sensitizes triple-negative breast cancer (TNBC) cells to chemotherapy in preclinical models. Given the high prevalence of EGFR overexpression in TNBC, we conducted a single-arm phase II study of panitumumab (anti-EGFR monoclonal antibody), carboplatin, and paclitaxel as the second phase of neoadjuvant therapy (NAT) in patients with doxorubicin and cyclophosphamide (AC)–resistant TNBC (NCT02593175).

Patients and Methods::

Patients with early-stage, AC-resistant TNBC, defined as disease progression or ≤80% reduction in tumor volume after four cycles of AC, were eligible for this study and received panitumumab (2.5 mg/kg i.v., every week × 13), paclitaxel (80 mg/m2 i.v. every week × 12), and carboplatin (AUC = 4 i.v., every 3 weeks × 4) as the second phase of NAT. A two-stage Gehan-type design was used to detect an improvement in the pathological complete response (pCR)/residual cancer burden class I (RCB-I) rate from 5% to 20%. Whole-exome sequencing was performed on diagnostic tumor biospecimens, where available.

Results::

From November 3, 2016, through August 23, 2021, 43 patients with AC-resistant TNBC were enrolled. The combined pCR/RCB-I rate was 30.2%. The most common treatment-related adverse events were neutropenia (72%) and anemia (61%), with 7 (16%), 16 (37%), and 8 (19%) patients experiencing grade 4 neutropenia, grade 3 neutropenia, and grade 3 anemia, respectively. No new safety signals were observed.

Conclusions::

This study met its primary endpoint (pCR/RCB-I = 30.2% vs. 5% in historical controls), suggesting that panitumumab should be evaluated as a component of NAT in patients with chemotherapy-resistant TNBC in a larger, randomized clinical trial.

Significance::

The epidermal growth factor receptor (EGFR) pathway has been implicated as a driver of chemotherapy resistance in triple-negative breast cancer (TNBC). Here, we evaluate the combination of panitumumab, carboplatin, and paclitaxel as the second phase of neoadjuvant therapy (NAT) in patients with AC-resistant TNBC. This study met its primary efficacy endpoint, and molecular alterations in EGFR pathway genes did not seem to influence response to the study regimen.

News (Medical) associated with Matuzumab

06 Mar 2025

·firstwordpharma.com

Merck KGaA keeps schtum on ongoing SpringWorks talks

Merck KGaA on Thursday reported its annual results for 2024, although investors eager for an update on a potential deal with SpringWorks Therapeutics were left frustrated. The German drugmaker simply reaffirmed that it is in advanced discussions about a possible acquisition of SpringWorks, although there is no certainty that an agreement will be signed. Rumours of a transaction between the parties first surfaced on February 10, with Merck confirming later the same day that talks were ongoing. A purchase of SpringWorks would give Merck the oral gamma secretase inhibitor Ogsiveo (nirogacestat), which is approved for desmoid tumours, as well as the MEK inhibitor mirdametinib, currently under review by the FDA for neurofibromatosis type 1-associated plexiform neurofibromas.The acquisition of SpringWorks would revitalise Merck's pipeline, following a number of recent setbacks, including the failure of a pair of Phase III studies for its lead oncology candidate xevinapant. While the company's healthcare segment posted 5% growth last year to €8.5 billion ($9.2 billion), driven by oncology — which was up 10.5% to €2 billion — it is heavily reliant on its 20-year-old drug Erbitux.Erbitux biosimilars on the horizonThe anti-EGFR monoclonal antibody generated sales in 2024 of €1.2 billion, up 13.3% over the prior year. Merck noted that growth for Erbitux was led by Latin America, particularly Mexico, as well as Europe and China, tempered by negative pricing effects in Japan.Asked on an analyst call about the growth potential of Erbitux, particularly in China, Peter Guenter — CEO of Merck's healthcare unit — noted that sales of the product are forecast to increase this year, with biosimilars not expected to launch before 2026. Guenter indicated that China, which accounts for about 25% of Erbitux revenue, is "an important growth driver, but actually the brand is very dynamic across the world."While Erbitux faces competition in China from Simcere Pharmaceutical's Enlituo, Guenter clarified that the product — approved last June — is not classified as a biosimilar, but rather a non-comparable biologic. "And that has, of course, relatively important implications in terms of, you know, lack of substitution," Guenter explained, as well as inclusion on the reimbursement drug list and volume-based procurement programme.Merck's other key drug, the multiple sclerosis (MS) therapy Mavenclad, achieved blockbuster status in 2024 for the first time, posting an 11.1% increase in revenue to €1.1 billion. Meanwhile, its older MS treatment Rebif declined 11.6% to €626 million in line with the wider interferon market.For the current year, the firm expects sales in its healthcare unit to be between €8.3 billion and €8.9 billion, representing organic growth of up to 5%.Pipeline questions continueMerck also disclosed Thursday that the oral TLR7/8 inhibitor enpatoran failed to meet the primary endpoint of the systemic lupus erythematosus cohort of the mid-stage WILLOW study. Despite what Guenter called "a near miss" in the trial, the company plans further development of the drug, given "promising responses" in patient subgroups and the totality of data, including positive results from the cutaneous lupus erythematosus arm of WILLOW.Guenter explained "the good news is that we see clear responses in predefined subpopulations. So we can really say that the drug clearly hits the target." These subgroups include patients with skin manifestations within the lupus cluster, those with a strong interferon gene signature and also those with high steroid use at baseline.Meanwhile, chief financial officer Helene von Roeder noted that Inspirna "informed [us] about negative top-line data" from an ongoing Phase II trial of ompenaclid in RAS-mutated advanced or metastatic colorectal cancer. The SLC6A8 inhibitor — also known as RGX-202 — was the focus of a licensing agreement between the parties last year. However, von Roeder indicated that the mid-stage failure means "we will not exercise the US option" on the drug, but will instead record an impairment charge of around €15 million in the current quarter.

Drug ApprovalPhase 2AcquisitionLicense out/inPhase 3

05 Sep 2022

·www.prnewswire.com

Jacobio Completes First Dose of IIa Clinical Trial of JAB-21822 on KRAS G12C and STK11 Co-mutation in China

BEIJING, Sept. 1, 2022 /PRNewswire/ -- JacobioPharma (1167.HK) announced that the company has dosed the first non-small cell lung cancer (NSCLC) patient with KRAS G12C and STK11 co-mutation in the Phase IIa trial of KRAS G12C inhibitor JAB-21822 in China. JAB-21822 is a KRAS G12C inhibitor independently developed by Jacobio utilizing the allosteric inhibitor technology, which is now used as the front-line treatment for advanced or metastatic NSCLC patients with KRAS G12C and STK11 co-mutation. In China, there are approximately 40,000 new patients with tumors harboring KRAS G12C mutation every year. STK11 is an in-parallel biomarker of KRAS G12C. According to relevant studies, non-small cell lung cancer patients with STK11 and KRAS G12C co-mutation receiving KRAS G12C inhibitor treatment have a higher objective response rate in clinical study. "JAB-21822 is the first and only clinical stage drug approved for first-line treatment of STK11 and KRAS G12C co-mutated non-small cell lung cancer in China. JAB-21822 is independently developed by Jacobio, which has potential to bring better treatment options to patients based on efficacy and safety," said Dr. WANG Yinxiang, Chairman and CEO of Jacobio. JAB-21822 is the best-in-class potential project for KRAS G12C inhibitors. The preliminary clinical date of the Phase I study of JAB-21822 published at the 2022 annual meeting of American Society of Clinical Oncology (ASCO) shows that as of April 1, 2022, a total of 72 patients with advanced solid tumors were enrolled, and efficacy was assessed for 32 NSCLC patients with KRAS G12C mutation. The overall response rate (ORR) was 56.3% (18/32) and the disease control rate (DCR) was 90.6% (29/32). Currently, JAB-21822 is simultaneously undergoing clinical trials for monotherapy and combination therapy in China, the United States and Europe, including the monotherapy for NSCLC with KRAS G12C mutation, pancreatic ductal carcinoma and colorectal cancer; the combination therapy with EGFR monoclonal antibody; and the combination therapy with JAB-3312, a self-developed SHP2 inhibitor of the Company. About JAB-21822 JAB-21822 is a KRAS G12C inhibitor independently developed by the Company. The Company has initiated a number of Phase I/II clinical trials in China, the United States and Europe for patients with advanced solid tumors, including monotherapy for STK11 co-mutated non-small cell lung cancer in the front-line setting; combination therapy with SHP2 inhibitor, anti-PD-1 monoclonal antibody and Cetuximab. About Jacobio Jacobio Pharma (1167.HK) is committed to developing and providing new and innovative products and solutions to improve people's health. Our pipeline revolves around novel molecular targets on six major signalling pathways: KRAS, immune checkpoints, tumor metabolism, P53, RB and MYC. We aim for our key projects to be among the top three in the world. Our vision is to become a global leader recognized for our impact in drug R&D together with our partners. Jacobio has R&D centers in Beijing, Shanghai and Boston with our Induced Allosteric Drug Discovery Platform (IADDP) and our iADC Platform. Please visit us at www.jacobiopharma.com SOURCE Jacobio Pharma

CollaborateAntibodyASCOADCPhase 2

18 Jul 2022

·www.globenewswire.com

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-601 and Cetuximab Combination

ERAS-601, a potential best-in-class SHP2 inhibitor, is being investigated alone and in combination in the ongoing FLAGSHP-1 Phase 1/1b trial Erasca previously signed CTCSAs with Lilly and Pfizer to evaluate cetuximab and encorafenib in combination with ERK1/2 inhibitor ERAS-007 SAN DIEGO, July 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a clinical trial collaboration and supply agreement (CTCSA) with Eli Lilly and Company for Lilly’s anti-EGFR antibody cetuximab (ERBITUX®). This agreement will support Erasca’s ongoing Phase 1/1b FLAGSHP-1 trial, a clinical proof-of-concept trial evaluating ERAS-601, an oral SHP2 inhibitor, in various combinations, including with cetuximab for the treatment of triple wildtype (KRAS/NRAS/BRAF wildtype) metastatic colorectal cancer (CRC) and human papillomavirus (HPV)-negative advanced head and neck squamous cell carcinoma (HNSCC). Erasca is the sponsor of the trial, and Lilly is supplying cetuximab at no cost. Erasca previously signed CTCSAs with Lilly and Pfizer, respectively, to evaluate cetuximab and encorafenib (BRAFTOVI®) in combination with Erasca’s ERK1/2 inhibitor, ERAS-007, as part of Erasca’s HERKULES-3 Phase 1b/2 trial. “We are pleased to enter another clinical trial collaboration with Lilly to explore cetuximab in combination with ERAS-601, our SHP2 inhibitor, in EGFR-driven cancers that are highly dependent on RAS/MAPK signaling,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “Dual inhibition of EGFR and SHP2, a convergent RTK signaling node, has the potential to broaden and deepen responses relative to cetuximab monotherapy and delay onset of resistance in cancers like triple wildtype metastatic CRC and HPV-negative advanced HNSCC.” Approximately 1.5 million cases of CRC are diagnosed annually worldwide, with triple wildtype CRC, representing nearly 50% of all cases. HNSCC is one of the most common cancers worldwide, with around 0.7 million new cases annually of which 70-75% are HPV-negative HNSCC. While there are treatment options available in these tumor types, treatment resistance continues to limit long-term durability. The clinical development of this combination was supported by preclinical data Erasca presented at the 2022 American Association for Cancer Research (AACR) annual meeting demonstrating ERAS-601 in combination with cetuximab enhanced anti-proliferative activity and inhibited tumor growth over either agent alone in models of HPV-negative HNSCC and triple wildtype CRC. About ERAS-601ERAS-601 is a potential best-in-class oral, selective SHP2 inhibitor being investigated alone or in combination. SHP2 acts as a convergent node for receptor tyrosine kinase (RTK) signaling, relaying growth and survival signals from RTKs to intracellular signaling pathways. ERAS-601 is being investigated across a series of clinical trials that span multiple tumor types and include both monotherapy and combinations with approved and investigational agents. FLAGSHP-1 is a Phase 1/1b dose escalation trial evaluating ERAS-601 as a monotherapy in advanced solid tumors and in combination in triple wildtype CRC and HPV-negative HNSCC. HERKULES-2 is a Phase 1b/2 master protocol clinical trial that includes evaluation of ERAS-601 in combination with various agents in patients with non-small cell lung cancer. About ErascaAt Erasca, our name is our mission: To erase cancer. We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Our company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. We have assembled what we believe to be the deepest RAS/MAPK pathway-focused pipeline in the industry. We believe our team’s capabilities and experience, further guided by our scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer. Cautionary Note Regarding Forward-Looking StatementsErasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to: our expectations regarding the potential therapeutic benefits of our product candidates, including ERAS-601 and ERAS-007; our expectations regarding the preclinical data for ERAS-601 being indicative of future clinical results; our beliefs regarding market sizes and opportunities; and the planned advancement of our development pipeline, including the clinical development plans for ERAS-601 and ERAS-007. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: our approach to the discovery and development of product candidates based on our singular focus on shutting down the RAS/MAPK pathway, a novel and unproven approach; delays in our preclinical and clinical development programs; our dependence on third parties to conduct manufacturing, research, and preclinical and clinical testing; unexpected adverse side effects or inadequate efficacy of our product candidates that may limit their development, regulatory approval, and/or commercialization, or may result in recalls or product liability claims; unfavorable results from preclinical studies or clinical trials; results from preclinical studies or early clinical trials not necessarily being predictive of future results; regulatory developments in the United States and foreign countries; our ability to obtain and maintain intellectual property protection for our product candidates and maintain our rights under intellectual property licenses; our ability to fund our operating plans with our current cash, cash equivalents, and investments; our ability to maintain undisrupted business operations due to the COVID-19 pandemic; unstable market and economic conditions having serious adverse consequences on our business, financial condition and stock price; and other risks described in our prior filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K for the year ended December 31, 2021, and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. ERBITUX® is a registered trademark owned by or licensed to Eli Lilly and Company, its subsidiaries, or affiliates. BRAFTOVI® is a registered trademark owned by or licensed to Pfizer Inc., its subsidiaries, or affiliates. Contact:Joyce AllaireLifeSci Advisors, LLCjallaire@lifesciadvisors.com

CollaborateAntibodySmall molecular drugAACR

100 Deals associated with Matuzumab

External Link

KEGG	Wiki	ATC	Drug Bank
-	Matuzumab	-	DB05101

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Adenocarcinoma of Esophagus	Phase 2	Germany	Merck KGaA	31 Aug 2005
Adenocarcinoma of Esophagus	Phase 2	Spain	Merck KGaA	31 Aug 2005
Adenocarcinoma of Esophagus	Phase 2	Switzerland	Merck KGaA	31 Aug 2005
Adenocarcinoma of Esophagus	Phase 2	United Kingdom	Merck KGaA	31 Aug 2005
Metastatic gastroesophageal adenocarcinoma	Phase 2	Germany	Merck KGaA	31 Aug 2005
Metastatic gastroesophageal adenocarcinoma	Phase 2	Spain	Merck KGaA	31 Aug 2005
Metastatic gastroesophageal adenocarcinoma	Phase 2	Switzerland	Merck KGaA	31 Aug 2005
Metastatic gastroesophageal adenocarcinoma	Phase 2	United Kingdom	Merck KGaA	31 Aug 2005
Non-Small Cell Lung Cancer	Phase 2	United States	EMD Serono, Inc.	31 May 2005
Non-Small Cell Lung Cancer	Phase 2	Austria	EMD Serono, Inc.	31 May 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASCO2019	Not Applicable	Squamous cell carcinoma of head and neck metastatic	15	Cetuximab+Low-dose chemotherapy+Anti-PD1 therapy	nygwwnrpgw(ttfxqdsrga) = Six patients (40%) died: 2 due to progression of disease, 1 due to tumour bleeding, 2 due to pneumonia, and 1 due to fungemia. qmezcozous (tiserrhiap )	Positive	26 May 2019
NCT00215644 (MATRIX EG, CTgov)	Phase 2	Adenocarcinoma of Esophagus \| Esophageal Carcinoma \| Metastatic gastroesophageal adenocarcinoma	72	Matuzumab+cisplatin+epirubicin+Capecitabine (Epirubicin, Cisplatin, Capecitabine (ECX)+Matuzumab)	fqlunsyhkf = ydcwaaifhv igxbcweqwq (xbmbrotflk, peitlscrzu - gzihrbeest) View more	-	02 Nov 2018
				cisplatin+epirubicin+Capecitabine (ECX Only)	fqlunsyhkf = fkzxnvchbw igxbcweqwq (xbmbrotflk, vvuegndyjk - djfjffbqqg) View more
NCT00111839 (CTgov)	Phase 2	Non-Small Cell Lung Cancer	150	Pemetrexed (Pemetrexed Alone)	gslgocmjzv = zoxxvnbnfh mvvjuevcjs (kkzimgetbh, evbbeqzpnu - idpqhsnuiu) View more	-	06 Apr 2018
				Matuzumab+Pemetrexed (Pemetrexed Plus Matuzumab 800 mg Per Week)	gslgocmjzv = yfxzozlhgu mvvjuevcjs (kkzimgetbh, pnvyskavxt - euombxmxgo) View more
ASCO2014	Not Applicable	Metastatic Colorectal Carcinoma	195	anti-EGFR monoclonal antibody (CIMP-high)	lcqcvwwqah(snqqdgtlqe) = rwciragnfk wadbyjdefq (lerhulpemb )	-	20 May 2014
				anti-EGFR monoclonal antibody (CIMP-low)	lcqcvwwqah(snqqdgtlqe) = jfpmeutupg wadbyjdefq (lerhulpemb )
ASCO2011	Not Applicable	Nasopharyngeal Carcinoma	34	Nimotuzumab	kzbancvxew(ikxtmzeqsz) = kwpskmbpfx odfnwgrofc (fbwgqkjtay ) View more	-	20 May 2011
				Cetuximab	kzbancvxew(ikxtmzeqsz) = fvlggqqywz odfnwgrofc (fbwgqkjtay ) View more
NCT00215644 (Pubmed \| Ann Oncol)	Phase 2	Gastrooesophageal junction cancer First line	72	Matuzumab plus ECX	bkntvbltjn(bctoaguqfi) = bjogywjcuj pjcboxemtl (yzzmjbndvj, 17 - 49) View more	Negative	01 Nov 2010
				ECX alone	bkntvbltjn(bctoaguqfi) = svrxwjbske pjcboxemtl (yzzmjbndvj, 41 - 74) View more
ASCO2005	Phase 1	HR-positive/HER2-low Solid Tumors	26	Matuzumab 400mg	rsxsopwlrc(tbwcuckhdl) = glgszmixsl yifspenbds (bjxqjobcun )	-	01 Jun 2005
				Matuzumab 800mg	rsxsopwlrc(tbwcuckhdl) = cmiyrfgyix yifspenbds (bjxqjobcun )
ASCO2004	Phase 1	Gastrointestinal Neoplasms	24	EMD 72000 100 mg	qmjidxvcbr(vkaxnporhl) = lhjxbavrcs bfkawtcywy (knqtvifbnf )	-	15 Jul 2004
				EMD 72000 200 mg	qmjidxvcbr(vkaxnporhl) = dbcyyatnxi bfkawtcywy (knqtvifbnf )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis